2005P-0411 | Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs | |||||||||||||||||||||||
FDA Comment Number : | EC2526 | |||||||||||||||||||||||
Submitter : | Ms. Karen Hamburg | Date & Time: | 02/15/2006 04:02:42 | |||||||||||||||||||||
Organization : | Ms. Karen Hamburg | |||||||||||||||||||||||
Category : | Drug Industry | |||||||||||||||||||||||
Issue Areas/Comments | ||||||||||||||||||||||||
GENERAL | ||||||||||||||||||||||||
GENERAL | ||||||||||||||||||||||||
Division of Dockets Management
Food and Drug Administration 5630 Fishers Lane, Room 1061 (HFA-305) Rockville, MD, 20852 RE: Docket 2005P-0411 Dear Sir or Madam: I have been taking bioidentical hormones. I consult with my physician, who prescribes bio-identical hormones specifically for me, and my pharmacist prepares them. The benefit of BHRT is that it is designed for me and I am concerned that Wyeth?s petition (Docket # 2005P-0411) would limit the ability of my physician and pharmacist to keep prescribing and preparing these individualized doses for me. The FDA should reject Wyeth?s petition. | ||||||||||||||||||||||||